Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Boston-Cambridge-Quincy, MA-NH MSA — October 2026
Boston biopharma splits: pharma majors expand, biotechs retrench.
Massachusetts biopharma employment fell 3.1% in 2025 even as Lilly more than doubled its local workforce to 1,423 and biotech R&D employment rebounded 2.7% year-over-year in early 2026.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Boston metro unemployment: 4.1% — vs 4.3% Massachusetts statewide, 4.1% national
- MA biopharma employment change (2025): -3.1% — First annual decline in over two decades
- MA biotech R&D employment growth: +2.7% — Year-over-year, early 2026, after 2025 decline
- MA labor force contraction: -81,000 — Since March 2025 peak, per Pioneer Institute
Key takeaways
Biostatistician pay is pulling away from the national market.
Metro median advertised pay of $149,374 against a national $131,958 — and rising locally while flat nationally — points to Boston-specific demand concentrated in data-intensive clinical and companywide analytics roles. Leaders benchmarking this function against national data risk underpricing it.
CRA pay is diverging locally and nationally in opposite directions.
Metro CRA advertised pay sits well below the national median ($76,416 versus $90,065) despite both markets trending up significantly, which may reflect heavier reliance on CRO-sourced CRA talent locally over in-house hiring. This gap is worth testing against actual retention data before assuming Boston employers can hold the line on CRA compensation.
Layoff-driven talent release is concentrated among specific companies.
Blueprint Medicines' 229-worker WARN filing and Foghorn Therapeutics' 40% reduction reflect company-specific setbacks — a lost partnership, a pipeline reset. Expect pockets of available specialized talent near these events, with the broader regulatory or CMC labor pool remaining tight.
Regulatory Affairs pay stability masks a national-to-local inversion.
Metro Regulatory Affairs Specialist pay ($121,234) sits well above a declining national median ($103,780, down moderately), suggesting Boston's regulatory talent premium is holding even as national demand for the role softens. Current conditions suggest treating this as a structural local premium likely to persist.
Median advertised pay by role — Boston-Cambridge-Quincy, MA-NH MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $111,024 | $136,679 | $148,973 | Stable | $130,339 |
| Clinical Research Associate | $54,230 | $76,416 | $97,000 | Significant increase | $90,065 |
| Lab Technician | $43,460 | $54,080 | $57,500 | Stable | $47,840 |
| Regulatory Affairs Specialist | $87,603 | $121,234 | $135,202 | Stable | $103,780 |
| Clinical Data Manager | $100,354 | $123,031 | $152,355 | Moderate decline | $123,653 |
| Biostatistician | $104,067 | $149,374 | $163,289 | Significant increase | $131,958 |
| Validation Engineer | $95,693 | $113,079 | $123,760 | Stable | $106,478 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Boston metro unemployment held at 4.1% in August against a 4.3% Massachusetts statewide rate, even as the state's labor force contracted by roughly 81,000 since March 2025, suggesting fewer candidates are actively searching even as broader job market conditions remain largely intact. Massachusetts biopharma employment fell 3.1% in 2025, yet biotech R&D employment rebounded 2.7% year-over-year in early 2026, with pharma majors Sanofi and Lilly expanding headcount while mid-stage biotechs like Foghorn Therapeutics cut 40% of staff after a partnership collapse — a bifurcated market shaped by company stage and deal flow.
What it means
Scientist concentration at double the national share (25% versus 12%) means Boston employers compete for the same narrow credential pool even as overall headcount softens, and build-vs-outsource calculus on CRO/CDMO partnerships should account for this persistent scarcity as a structural condition. Biomanufacturing's return to growth (238 jobs added after two years of decline) signals Massachusetts's advantage lies in advanced-modality manufacturing talent over volume production — a distinction that should inform where leaders build internal capability versus outsource. Consider reviewing regulatory affairs, CMC, and program leadership compensation now, before Lilly- and Sanofi-scale expansion pulls harder on the same local talent pool.
Looking ahead
Early indicator: Watch whether Blueprint Medicines' and Foghorn Therapeutics' laid-off regulatory, CMC and clinical staff surface in the Cambridge-area candidate pool over the next two months — a meaningful test of whether specialized talent scarcity eases locally.
Worth watching: Massachusetts' $40 million in tax incentives tied to 1,644 new jobs across 38 life sci companies, paired with $3.45 billion in first-half VC funding, may translate into fresh hiring announcements from mid-stage biotechs through year-end.
Potential inflection point: Statewide labor force contraction of 81,000 since March 2025, if it continues, could tighten the experienced CRA and CMC candidate pool further even where company-level hiring slows, reinforcing a candidate-driven market for clinical operations talent.
Expected: October BLS unemployment data for the Boston-Cambridge-Newton MSA releases mid-November — watch for confirmation of whether the metro's 4.1% rate held or ticked toward the statewide 4.3%, which would signal broader softening beyond biopharma-specific layoffs.
Sources
- Pioneer Institute / BLS — Massachusetts labor force shrank by ~81,000 since March 2025 peak
- MassBio / state labor data — Massachusetts biopharma employment fell 3.1% in 2025
- Massachusetts life sciences workforce research — Scientists comprise 25% of MA life sciences workforce vs 12% nationally
- Layoff Atlas — Blueprint Medicines filed WARN notice for 229 workers in Cambridge
- Massachusetts state economic development data — 38 life sciences companies received $40 million in tax incentives for 1,644 jobs
- U.S. Bureau of Labor Statistics — Boston-Cambridge-Newton MSA unemployment at 4.1% in August 2026
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.